Consejo Nacional de Salud

392
32 Bueno J, Sanchez E, Fludarabine, Cytarabine,
Topotecan in Treating Patients With Relapsed
or Refractory Acute Myeloid Leukemia (FLAT),
PETHEMA Foundation
33 Bueno J, Sanchez E, Fludarabine, Cytarabine,
Topotecan in Treating Patients With Relapsed
or Refractory Acute Myeloid Leukemia (FLAT),
PETHEMA Foundation
34 American Cancer Society, Detalied Guide: Leukaemia
– Acute Lynphocitic (ALL) 08-03-2007
35 American Cancer Society, Detailed Guide: Leukemia
- Chronic Myeloid (CML) Treatment of Chronic
Myeloid Leukemia by Phase, 09/15/2008
36 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright
T, Hainsworth J, Heim W, Berlin J, Baron
A, Griffing S, Holmgren E, Ferrara N, Fyfe G,
Rogers B, Ross R, Kabbinavar F, Bevacizumab
plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer, The New England
Journal of Medicine ISSN 0028-4793 CODEN,
NEJMAG 2004, vol. 350, no23, pp. 2335-2342
37 Shelley M, Harrison C, Coles B, Stafforth J, Wilt T,
Mason M. Chemotherapy for hormone-refractory
prostate cancer. Cochrane Database of Systematic
Reviews 2006, Issue 4. Art. No.: CD005247.
DOI: 10.1002/14651858.CD005247.pub2.
38 Non-small Cell Lung Cancer Collaborative
Group. Chemotherapy for non-small cell lung
cancer. Cochrane Database of Systematic Reviews
2000, Issue 2. Art. No.: CD002139. DOI:
10.1002/14651858.CD002139
39 Agra Y, Pelayo M, Sacristan M, Sacristán A, Serra
C, Bonfill X. Chemotherapy versus best supportive
care for extensive small cell lung cancer. Cochrane
Database of Systematic Reviews 2003, Issue 4.
Art. No.: CD001990. DOI: 10.1002/14651858.
CD001990
40 Solà I, Thompson E, Subirana M, López C, Pascual
A. Non-invasive interventions for improving
well-being and quality of life in patients with lung
cancer. Cochrane Database of Systematic Reviews
2004, Issue 4. Art. No.: CD004282. DOI:
10.1002/14651858.CD004282.pub2.
41 Yip D, Karapetis C, Strickland A, Steer CB, Goldstein
D. Chemotherapy and radiotherapy for inoperable
advanced pancreatic cancer. Cochrane
Database of Systematic Reviews 2006, Issue 3.
Art. No.: CD002093. DOI: 10.1002/14651858.
CD002093.pub2.
42 Wagstaff A J,Ibbotson T, Goa K L, Capecitabine:
A Review of its Pharmacology and Therapeutic
Efficacy in the Management of Advanced Breast
Cancer, Drugs 2003; 63 (2): 217-2360012-
6667/03/0002-0217/$33.00/ Adis International
Limited, Auckland, New Zealand
43 Saeki T, Kimura T, Toi M, Taguchi T, on behalf of
the Clinical Study Group of Capecitabine, A Pilot
Phase II Study of Capecitabine in Advanced or Recurrent
Breast Cancer, Breast Cancer Vol. 13 No.
1 January 2006
44 Ajani J, Review of Capecitabine as Oral Treatment
of Gastric, Gastroesophageal, and Esophageal
Cancers, Department of Gastrointestinal Medical
Oncology, The University of Texas M. D. Anderson
Cancer Center, Houston, Texas, American
Cancer Society DOI 10.1002/cncr.21986, Published
online 12 June 2006 in Wiley InterScience
(www.interscience.wiley.com)
45 Glynne-Jones R, Dunst J, Sebag-Montefiore D,
The integration of oral capecitabine into chemoradiation
regimens for locally advanced rectal cancer:
how successful have we been? , Annals of Oncology
17: 361–371, 2006, doi:10.1093/annonc/mdj052